BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Laquinimod: Phase III data

Top-line data from the double-blind, international Phase III BRAVO trial in 1,331 patients showed that once-daily 0.6 mg oral laquinimod missed the primary endpoint of significantly reducing ARR from baseline to 2 years vs. placebo (0.29 vs. 0.37, p=0.075). However, a pre-specified sensitivity analysis that adjusted for dissimilarities in 2 baseline MRI characteristics - the percent of patients with gadolinium-enhanced lesions and the volume of T2 lesions - between placebo, laquinimod and the active control

Read the full 362 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >